Sonar to Improve the Quality of AI-Generated Code, Provide Automated Fix Recommendations
3.10.2024 16:00:00 EEST | Business Wire | Press release
Sonar, the leading Clean Code solution provider, today announced two new product capabilities for today’s AI-driven software development ecosystem. These new capabilities are designed to support better software development in two critical and distinct ways – Sonar AI Code Assurance and Sonar AI CodeFix improve the quality of code produced by generative AI and enhance Sonar’s offering with AI to deliver a better developer experience, respectively. Both capabilities deepen Sonar’s commitment to the delivery of high-quality, secure code and increasing developer productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003439224/en/
Sonar introduces AI Code Assurance and AI CodeFix to improve the quality of code produced by generative AI. (Photo: Business Wire)
AI Code Assurance helps organizations ensure the quality of AI-generated code by thoroughly analyzing the codebase for issues, ensuring that projects using AI tools to generate code meet high standards of quality and security. Today, bad code is already estimated to cost businesses more than a trillion dollars, making it critical for AI-generated code, which promises to increase the volume of code written, to be comprehensively checked for quality and security issues.
“AI is transforming the way developers work, streamlining processes, and reducing the toil associated with writing code. As the adoption of AI coding assistants grows, however, we are seeing a new issue emerge: code accountability. AI-generated code needs review by developers, but accountability for doing this is increasingly diluted. As a result, we’re seeing the review step frequently being shortchanged,” said Tariq Shaukat, CEO of Sonar. “With AI Code Assurance, we’re helping organizations ensure that AI written code receives the high level of quality and security review that you would expect from your developers.”
AI CodeFix allows developers to seamlessly resolve issues detected by Sonar's code analysis engine with a single click, directly within their workflow. The AI-powered fix recommendations help streamline developer workflows, speed up issue remediation, and improve the developer experience. As leading research has established, developer experience improves with the automation that AI provides. For example, McKinsey reported that developers using generative AI tools in their work stream are “twice as likely to report overall happiness, fulfillment, and a state of flow” than those who aren’t.
“AI CodeFix helps developers streamline their workflow and ramp up their productivity. Rather than switching between solutions or manual efforts, we’re putting remediation options for Sonar-identified issues right in front of the people working on them – and giving them the ability to fix the issues in an instant. We’re excited to see how our users adopt this capability and better understand how we can further integrate AI into our solutions to improve the developer experience,” said Fabrice Bellingard, VP of Product at Sonar.
The features are currently available for both SonarQube and SonarCloud.
AI Code Assurance for Confidence in Code Quality
With AI Code Assurance for SonarQube and SonarCloud, developers can be confident that their AI-generated code is clean and secure. By implementing the Sonar AI Code Assurance workflow, organizations have the assurance that all code (AI-generated and human-developed) has been thoroughly scanned for issues and that projects leveraging AI tools are meeting high standards of quality and security.
AI Code Assurance capabilities include:
- Project Tagging: Developers can easily tag projects that contain AI-generated code, initiating a comprehensive analysis through the Sonar AI Code Assurance workflow.
- Quality Gate Enforcement: An optimized quality gate for AI-generated code ensures that only code meeting strict quality and security standards is approved for production.
- AI Code Assurance Approved Badge: Projects that pass the quality gate receive a badge signifying that the code has gone through a rigorous AI-ready analysis.
AI CodeFix for Fast Issue Remediation
Fast-paced software development environments require solutions that enhance productivity, reduce time-to-market, and maintain high code quality. Today, millions of Sonar users can detect and fix issues in their code leveraging Sonar’s database of code rules and best practices. Now, at the click of a button, developers can use AI CodeFix to automatically generate solutions to issues in the same SonarQube and SonarCloud user interface where they review issues.
AI CodeFix capabilities include:
- Instant Code Fixes: Minimize manual debugging efforts and increase productivity by automatically generating code fix suggestions.
- Contextual Understanding of Sonar findings: Leverages LLMs to understand code context and provide relevant fixes.
- Seamless Integration: Developers fix issues directly within their IDE using SonarLint connected mode, ensuring a smooth workflow.
- Continuous Learning: Ongoing suggestion improvements based on user feedback
- Multi-Language Support: Supports flagship programming languages such as Java, JS/TS, C#, Python, and C/C++.
AI Code Assurance is now available on SonarQube and will be generally available in SonarCloud by the end of October. AI CodeFix is available for early access in SonarQube Enterprise Edition, SonarQube Data Center Edition, and SonarCloud Team and Enterprise plans.
For more information on the new features, visit our AI features page at https://www.sonarsource.com/solutions/ai/.
About Sonar
Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003439224/en/
Contacts
Media
Katie Hyman
Senior PR Manager for Sonar
(707) 291-1469
press@sonarsource.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom